Phase Ib Study of Plx3397, a Csf1R Inhibitor, and Paclitaxel in Patients with Advanced Solid Tumors

Rugo, Hope S.; Sharma, Nikunj; Reebel, Laura; Rodal, Mary Beth; Peck, AR; West, Brian L.; Marimuthu, A.; Karlin, David A.; Dowlati, Afshin; Le, Mai H.; Coussens, Lisa M.; Wesolowski, Robert

doi:10.1093/annonc/mdu331.7

Cited by 5 publications

(2 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Emactuzumab, as single agent or in combination with paclitaxel, did not reach an MTD. The safety profile, including asthenia, edema and asymptomatic liver enzyme elevations, was in line with previous reports on CSF-1R-targeting antibodies as monotherapy [7,22,23] and the combination of the CSF-1R kinase inhibitor pexidartinib and paclitaxel [24]. Kupffer cells play an important role in the clearance of serum enzymes, including AST, ALT, LDH, and CPK [12].…”

Section: Discussionsupporting

confidence: 85%

Phase I study of emactuzumab single agent or in combination with paclitaxel in patients with advanced/metastatic solid tumors reveals depletion of immunosuppressive M2-like macrophages

et al. 2019

View full text Add to dashboard Cite

Section: Discussionsupporting

confidence: 85%

Phase I study of emactuzumab single agent or in combination with paclitaxel in patients with advanced/metastatic solid tumors reveals depletion of immunosuppressive M2-like macrophages

et al. 2019

View full text Add to dashboard Cite

“…The dose of pexidartinib was selected based on safety and efficacy data from a previously reported phase 1b trial of pexidartinib and weekly paclitaxel in patients with advanced solid tumors. 12…”

Section: Resultsmentioning

confidence: 99%

A case report of vanishing bile duct syndrome after exposure to pexidartinib (PLX3397) and paclitaxel

et al. 2019

View full text Add to dashboard Cite

Pexidartinib (PLX3397) is a small molecule tyrosine kinase and colony-stimulating factor-1 inhibitor with FDA breakthrough therapy designation for tenosynovial giant-cell tumor, and currently under study in several other tumor types, including breast cancer, non-Hodgkin’s lymphoma, and glioblastoma. Here, we report a case of severe drug-induced liver injury requiring liver transplantation due to vanishing bile duct syndrome (VBDS) after exposure to pexidartinib in the I-SPY 2 Trial, a phase 2 multicenter randomized neoadjuvant chemotherapy trial in patients with Stage II–III breast cancer. We also review the current literature on this rare, idiosyncratic, and potentially life-threatening entity.

show abstract

Role of immunotherapy in bladder cancer: past, present and future

Butt

Malik

2018

Cancer Chemother Pharmacol

View full text Add to dashboard Cite

As research focus in oncology has recently shifted from oral targeted therapy to immunomodulation, the era of successful drug development in bladder cancer has just begun. This has led to unprecedented approval of five immunotherapeutic agents by regulatory agencies for metastatic bladder cancer within a span of 12 months. With an initial triumph of anti-programmed cell death-1 (anti-PD-1) and anti-programmed cell death ligand-1 (anti-PDL-1) drugs, ongoing efforts are aimed at identification and validation of new druggable immune targets to consolidate the initial gains. In this paper, we review the role of immunotherapy in the treatment of bladder cancer as well as the various emerging immunotherapeutic agents and their possible use in bladder cancer.

show abstract

Phase Ib Study of Plx3397, a Csf1R Inhibitor, and Paclitaxel in Patients with Advanced Solid Tumors

Cited by 5 publications

References 0 publications

Phase I study of emactuzumab single agent or in combination with paclitaxel in patients with advanced/metastatic solid tumors reveals depletion of immunosuppressive M2-like macrophages

Phase I study of emactuzumab single agent or in combination with paclitaxel in patients with advanced/metastatic solid tumors reveals depletion of immunosuppressive M2-like macrophages

A case report of vanishing bile duct syndrome after exposure to pexidartinib (PLX3397) and paclitaxel

Role of immunotherapy in bladder cancer: past, present and future

Contact Info

Product

Resources

About